fluticasone-umeclidinium-vilanterol Trelegy
Selected indexed studies
- [Use of fluticasone/umeclidinium/vilanterol in France: A population based study]. (Rev Mal Respir, 2025) [PMID:40537300]
- Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study. (Int J Chron Obstruct Pulmon Dis, 2026) [PMID:42136913]
- Comparative effectiveness and safety of fluticasone-based versus beclometasone-based single-inhaler triple therapies in patients with chronic obstructive pulmonary disease: a population-based cohort study. (Int J Clin Pharm, 2026) [PMID:41201486]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study. (2024) pubmed
- [Use of fluticasone/umeclidinium/vilanterol in France: A population based study]. (2025) pubmed
- Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study. (2026) pubmed
- Comparative effectiveness and safety of fluticasone-based versus beclometasone-based single-inhaler triple therapies in patients with chronic obstructive pulmonary disease: a population-based cohort study. (2026) pubmed
- Cost-Effectiveness Analysis of Triple Combination Preparations in the Treatment of Moderate-to-Severe Chronic Obstructive Pulmonary Disease. (2021) pubmed
- Single inhaler with beclometasone, formoterol, and glycopyrronium versus triple therapies in adults with uncontrolled asthma: a systematic review and meta-analysis. (2025) pubmed
- Cardiac disorders associated with compound long-acting bronchodilators for inhalation: a pharmacovigilance analysis of the FDA adverse event reporting system database. (2026) pubmed